Caspase inhibition reduces cardiac myocyte dyshomeostasis and improves cardiac contractile function after major burn injury

J Appl Physiol (1985). 2007 Jul;103(1):323-30. doi: 10.1152/japplphysiol.01255.2006. Epub 2007 Apr 12.

Abstract

In the heart, thermal injury activates a group of intracellular cysteine proteases known as caspases, which have been suggested to contribute to myocyte inflammation and dyshomeostasis. In this study, Sprague-Dawley rats were given either a third-degree burn over 40% total body surface area plus conventional fluid resuscitation or sham burn injury. Experimental groups included 1) sham burn given vehicle, 400 microl DMSO; 2) sham burn given Q-VD-OPh (6 mg/kg), a highly specific and stable caspase inhibitor, 24 and 1 h prior to sham burn; 3) burn given vehicle, DMSO as above; 4) burn given Q-VD-OPh (6 mg/kg) 24 and 1 h prior to burn. Twenty-four hours postburn, hearts were harvested and studied with regard to myocardial intracellular sodium concentration, intracellular pH, ATP, and phosphocreatine (23Na/31P nuclear magnetic resonance); myocardial caspase-1, -3,and -8 expression; myocyte Na+ (fluorescent indicator, sodium-binding benzofurzan isophthalate); myocyte secretion of TNF-alpha, IL-1beta, IL-6, and IL-10; and myocardial performance (Langendorff). Burn injury treated with vehicle alone produced increased myocardial expression of caspase-1, -3, and -8, myocyte Na+ loading, cytokine secretion, and myocardial contractile depression; cellular pH, ATP, and phosphocreatine were stable. Q-VD-OPh treatment in burned rats attenuated myocardial caspase expression, prevented burn-related myocardial Na+ loading, attenuated myocyte cytokine responses, and improved myocardial contraction and relaxation. The present data suggest that signaling through myocardial caspases plays a pivotal role in burn-related myocyte sodium dyshomeostasis and myocyte inflammation, perhaps contributing to burn-related contractile dysfunction.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Amino Acid Chloromethyl Ketones / pharmacology*
  • Amino Acid Chloromethyl Ketones / therapeutic use
  • Animals
  • Burns / complications*
  • Burns / drug therapy
  • Burns / metabolism
  • Burns / physiopathology
  • Calcium / metabolism
  • Caspase 1 / metabolism
  • Caspase 3 / metabolism
  • Caspase 8 / metabolism
  • Caspase Inhibitors*
  • Caspases / metabolism
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Cysteine Proteinase Inhibitors / therapeutic use
  • Disease Models, Animal
  • Heart Diseases / etiology
  • Heart Diseases / metabolism
  • Heart Diseases / physiopathology
  • Heart Diseases / prevention & control*
  • Homeostasis
  • Hydrogen-Ion Concentration
  • Interleukin-10 / metabolism
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Magnetic Resonance Spectroscopy
  • Male
  • Myocardial Contraction / drug effects*
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / metabolism
  • Phosphocreatine / metabolism
  • Quinolines / pharmacology*
  • Quinolines / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Severity of Illness Index
  • Signal Transduction / drug effects*
  • Sodium / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Ventricular Pressure / drug effects

Substances

  • Amino Acid Chloromethyl Ketones
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Interleukin-1beta
  • Interleukin-6
  • Quinolines
  • Tumor Necrosis Factor-alpha
  • quinoline-val-asp(OMe)-CH2-OPH
  • Phosphocreatine
  • Interleukin-10
  • Adenosine Triphosphate
  • Sodium
  • CASP8 protein, human
  • Caspase 3
  • Caspase 8
  • Caspases
  • Caspase 1
  • Calcium